Department of Ophthalmology, Ege University Faculty of Medicine, Bornova, Izmir, Turkey.
J Glaucoma. 2010 Oct-Nov;19(8):556-60. doi: 10.1097/IJG.0b013e3181ca76d9.
To evaluate the intraocular pressure (IOP) control and graft survival after Ex-PRESS mini glaucoma shunt implantation in refractory postpenetrating keratoplasty glaucoma.
The study included postpenetrating keratoplasty glaucoma cases unresponsive to medical antiglaucomatous therapy in whom 15 Ex-PRESS mini glaucoma shunt implantation was carried out. All glaucoma shunt implantations were performed in a separate session after penetrating keratoplasty. Nine operations were performed under general anesthesia and 6 were performed under local anesthesia. Topical antibiotherapy and topical corticosteroids were used during the postoperative first month.
Mean age of the study population was 37.4 years (range: 10 to 80 y). IOP decreased from 41.46 mm Hg (range: 26 to 80 mm Hg) to 12.06 mm Hg (range: 8 to 25 mm Hg) over a mean follow-up of 12.2 months (range: 8 to 19 mo) (P<0.001; Wilcoxon signed rank test). IOP was below 21 mm Hg in 14 of 15 eyes (93.3%) with or without antiglaucomatous drugs. Complete success (IOP<21 mm Hg without medication) rate was 86.6%. Average number of antiglaucomatous drug usage decreased from 3.20 (range: 2 to 4) preoperatively to 0.26 postoperatively (range: 0 to 3) (P<0.001; Wilcoxon signed rank test). In 93.3% of the cases, the decrease in IOP was 30% or above postoperatively. After Ex-PRESS implantation, clear grafts remained clear while edematous grafts became clearer due to IOP decrease. Neither biomicroscopy nor pachymetry showed worsening of preoperatively opaque grafts.
Ex-PRESS mini glaucoma shunt implantation may be an effective procedure for refractory postpenetrating keratoplasty glaucoma with acceptable graft failure rates in short term.
评估 Ex-PRESS 微创青光眼引流阀植入术治疗穿透性角膜移植术后难治性青光眼的眼压(IOP)控制和移植物存活率。
本研究纳入了对药物治疗反应不佳的穿透性角膜移植术后青光眼患者,共 15 例(15 只眼)接受 Ex-PRESS 微创青光眼引流阀植入术。所有青光眼引流阀植入术均在穿透性角膜移植术后的单独手术中进行。9 例手术在全身麻醉下进行,6 例在局部麻醉下进行。术后第一个月局部使用抗生素和皮质类固醇治疗。
研究人群的平均年龄为 37.4 岁(范围:10 至 80 岁)。平均随访 12.2 个月(范围:8 至 19 个月)后,IOP 从 41.46mmHg(范围:26 至 80mmHg)降至 12.06mmHg(范围:8 至 25mmHg)(P<0.001;Wilcoxon 符号秩检验)。15 只眼中有 14 只(93.3%)眼压在 21mmHg 以下,无论是否使用抗青光眼药物。完全成功率(眼压<21mmHg 且无需药物治疗)为 86.6%。平均抗青光眼药物使用量从术前的 3.20(范围:2 至 4)降至术后的 0.26(范围:0 至 3)(P<0.001;Wilcoxon 符号秩检验)。在 93.3%的病例中,术后 IOP 下降 30%或更多。植入 Ex-PRESS 后,由于眼压降低,透明移植物保持透明,水肿移植物变得更清晰。生物显微镜和角膜测厚术均未显示术前不透明移植物恶化。
Ex-PRESS 微创青光眼引流阀植入术治疗穿透性角膜移植术后难治性青光眼可能是一种有效的方法,短期结果显示移植物失败率可接受。